BioPharma Resources

NDA 018564 · Otsuka Icu Medcl

Dextrose 20% In Plastic Container

Dextrose · Injection

Last checked: Nov 19, 2026Latest source record: May 14, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

Mar 23, 1982

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3,797

712 Phase 3, 359 recruiting

FAERS reports

13,727

12,671 serious, 2,102 with death reported

AI brief across all sources

Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 2, 2025.

Dextrose Injection 20%, 30%, 40%, 50% and 70%, mixed with amino acids or other compatible intravenous fluids, is indicated as a source of calories for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Dextrose Injection 20%, 30%, 40%, 50% and 70%, mixed with amino acids or other compatible intravenous fluids, is indicated as a source of calories for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient or contraindicated ( 1 )

Mechanism: Dextrose Injection is used to supplement nutrition by providing glucose parenterally. Dextrose is oxidized to carbon dioxide and water, yielding energy.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 23, 1982 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • DEXTROSE 20% IN PLASTIC CONTAINER · DEXTROSE 20GM/100ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dextrose" as an intervention, any sponsor and status, largest first.

All 3,797 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • myelosuppression1,855
  • off label use1,091
  • nausea1,037
  • drug ineffective973
  • vomiting963
  • acute kidney injury807
  • pyrexia731
  • white blood cell count decreased714
  • dyspnoea683
  • sepsis588
  • abdominal pain544
  • hypotension532

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200453
200536
200649
200740
200864
200983
2010117
2011145
2012148
2013128
2014395
2015199
2016312
2017284
2018380
2019487
2020611
2021962
20221,571
20232,020
20241,949
20251,980
20261,712

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,414 on PubMed

Sponsor: Otsuka

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.